Antiva is developing novel topical therapies to treat pre-cancerous cervical lesions as well as the HPV infections that cause these lesions. Currently, there is no treatment for HPV infection; women must wait and see whether their infection clears by itself or progresses to more advanced disease. We are developing a first-in-class therapy that would give women the ability to treat themselves in the privacy of their own homes when their infection is first diagnosed. Our therapy also provides a non-surgical option for women whose disease is more advanced.

Our passionate, experienced team is dedicated to improving health outcomes and access to care worldwide by developing a simple and convenient non-surgical approach to treat HPV and precancerous lesions, supporting the World Health Organization’s global Cervical Cancer Elimination Initiative.

Antiva Biosciences, Inc. is a venture-backed biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by HPV, before they progress to invasive cancers. Our lead product, for treatment of cervical intraepithelial neoplasias (HSIL or CIN 2,3), utilizes antiviral prodrug chemistry developed by Dr. Karl Hostetler at the University of California San Diego. Our goal is to provide a non-surgical alternative for treatment of CIN 2,3 that preserves women’s reproductive health, can be self-administered in the privacy of their homes, and improves access to care in underserved communities where OB/GYN resources are scarce.

Our lead product also has the potential to treat earlier stage disease: HPV infection, the most common sexually transmitted infection in the world. We are actively exploring this opportunity to transform cervical care, allowing women to treat their HPV infection before it progresses to later stage disease, including cervical cancer, as well as reducing transmission and risk of cancer in their partners.